RxDoctor Payments Data

Caitlyn Haygood, PA

Internal Medicine · Buford, GANPI 1225781818

Payments from drug & device makers

$1,036in general payments, 2019–2025

Across 16 payments — averaging $64.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$240
  • Baxter Healthcare$210
  • Amgen$195
  • Novo Nordisk$133
  • AbbVie$96
  • Astellas Pharma US Inc$66
  • plus $95 from 4 others

What the payments were for

  • Food & beverage$75973%
  • Education$666%
  • Other$21020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,036 in reported general payments places this provider in the 65th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$33,810
Medicare patients
191
Services billed
3,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$87,682
JardianceEmpagliflozin48$64,567
EliquisApixaban29$38,733
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$34,908
JanuviaSitagliptin Phosphate15$16,421
MyrbetriqMirabegron14$13,785
Levothyroxine Sodium255$2,333
Gabapentin97$2,090
Albuterol Sulfate HfaAlbuterol Sulfate71$1,640
Atorvastatin Calcium210$1,505
Rosuvastatin Calcium153$1,397
Losartan Potassium131$1,113
Amlodipine Besylate252$1,078
Ezetimibe44$1,076
Celecoxib40$1,054

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$133$87,68254 claims
PfizerEliquis$32$38,73329 claims
GSKTrelegy Ellipta$20$34,90834 claims
Astellas Pharma US IncMyrbetriq$66$13,78514 claims
AbbVieSynthroid$96$95812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Buford

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →